These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 20890037

  • 1. [Cytokines in bone diseases. Osteoprotegerin and juvenile Paget's disease].
    Hosogane N, Miyamoto T.
    Clin Calcium; 2010 Oct; 20(10):1540-4. PubMed ID: 20890037
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Osteoprotegerin deficiency and juvenile Paget's disease.
    Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S.
    N Engl J Med; 2002 Jul 18; 347(3):175-84. PubMed ID: 12124406
    [Abstract] [Full Text] [Related]

  • 5. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA.
    J Pathol; 2006 May 18; 209(1):114-20. PubMed ID: 16482498
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation.
    Saki F, Karamizadeh Z, Nasirabadi S, Mumm S, McAlister WH, Whyte MP.
    J Bone Miner Res; 2013 Jun 18; 28(6):1501-8. PubMed ID: 23322328
    [Abstract] [Full Text] [Related]

  • 8. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
    Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D.
    J Bone Miner Res; 2006 Mar 18; 21(3):438-45. PubMed ID: 16491292
    [Abstract] [Full Text] [Related]

  • 9. Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7, Transcription Factor SP7).
    Whyte MP, Campeau PM, McAlister WH, Roodman GD, Kurihara N, Nenninger A, Duan S, Gottesman GS, Bijanki VN, Sedighi H, Veis DJ, Mumm S.
    Bone; 2020 Aug 18; 137():115364. PubMed ID: 32298837
    [Abstract] [Full Text] [Related]

  • 10. [Role of OPG in regulation of bone remodeling].
    Nakamichi Y, Udagawa N.
    Clin Calcium; 2006 Sep 18; 16(9):1463-68. PubMed ID: 16951469
    [Abstract] [Full Text] [Related]

  • 11. Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease.
    Naot D, Choi A, Musson DS, Simsek Kiper PÖ, Utine GE, Boduroglu K, Peacock M, DiMeglio LA, Cundy T.
    Bone; 2014 Nov 18; 68():6-10. PubMed ID: 25108083
    [Abstract] [Full Text] [Related]

  • 12. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N, Udagawa N, Suda T.
    Biochem Biophys Res Commun; 1999 Mar 24; 256(3):449-55. PubMed ID: 10080918
    [Abstract] [Full Text] [Related]

  • 13. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
    Menaa C, Barsony J, Reddy SV, Cornish J, Cundy T, Roodman GD.
    J Bone Miner Res; 2000 Feb 24; 15(2):228-36. PubMed ID: 10703924
    [Abstract] [Full Text] [Related]

  • 14. Pathogenesis of Paget's disease of bone.
    Ralston SH.
    Bone; 2008 Nov 24; 43(5):819-25. PubMed ID: 18672105
    [Abstract] [Full Text] [Related]

  • 15. Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.
    Whyte MP, Tau C, McAlister WH, Zhang X, Novack DV, Preliasco V, Santini-Araujo E, Mumm S.
    Bone; 2014 Nov 24; 68():153-61. PubMed ID: 25063546
    [Abstract] [Full Text] [Related]

  • 16. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype.
    Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tüysüz B, Yüksel B, Love D, International Hyperphosphatasia Collaborative Group.
    J Bone Miner Res; 2003 Dec 24; 18(12):2095-104. PubMed ID: 14672344
    [Abstract] [Full Text] [Related]

  • 17. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
    Whyte MP.
    Ann N Y Acad Sci; 2006 Apr 24; 1068():143-64. PubMed ID: 16831914
    [Abstract] [Full Text] [Related]

  • 18. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.
    J Bone Miner Res; 2000 Aug 24; 15(8):1459-66. PubMed ID: 10934644
    [Abstract] [Full Text] [Related]

  • 19. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin.
    Daroszewska A, Hocking LJ, McGuigan FE, Langdahl B, Stone MD, Cundy T, Nicholson GC, Fraser WD, Ralston SH.
    J Bone Miner Res; 2004 Sep 24; 19(9):1506-11. PubMed ID: 15312251
    [Abstract] [Full Text] [Related]

  • 20. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE, Bonnelye E.
    Medscape Womens Health; 2000 Mar 24; 5(2):5. PubMed ID: 10792853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.